A2AR antagonism leads also to regeneration of IL-2 and IFN-γ production by T cell and its combination with anti-PDL1 or anti-CTLA-4 treatment improves tumor regression, better than monotherapy (Willingham et al., 2018; Steingold and Hatfield, 2020) (Figure 2B). The gene discussed is ADORA2A; the disease is neoplasm.